arrow_back Trending Legislation
Share share

Support for Research on Valley Fever Treatment

This act aims to accelerate the development of drugs and prevention methods for coccidioidomycosis, also known as Valley Fever. By doing so, pharmaceutical companies can bring new therapies to market faster, potentially improving access to treatment and public health, especially in regions affected by this disease.
Key points
Coccidioidomycosis (Valley Fever) has been added to the list of tropical diseases eligible for the FDA's priority review voucher program.
Companies developing drugs for this disease may receive faster approval, encouraging investment in research and development.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
Print number: HR 6227
Sponsor: Rep. Schweikert, David [R-AZ-1]
Process start date: 2023-11-03
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Support for Research on Valley Fever Treatment

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 6227.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-11-03.

What are the main provisions?

Key points include:

  • Coccidioidomycosis (Valley Fever) has been added to the list of tropical diseases eligible for the FDA's priority review voucher program.
  • Companies developing drugs for this disease may receive faster approval, encouraging investment in research and development.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schweikert, David [R-AZ-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 6227

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health